Fig 1 - available via license: Creative Commons Attribution 4.0 International
Content may be subject to copyright.
Anti-TNFα mAb suppresses colorectal cancer growth in an orthotopic transplant model. (a) Schematic overview of the orthotopic transplant model of colorectal cancer and anti-TNFα mAb administration. (b) Mice subjected to orthotopic transplantation were administered CT26 cells into the cecum with and without anti-TNFα mAb. (c) The weight and volume of the tumor orthotopically transplanted into the cecum were recorded. Control group (n = 12), anti-TNFα mAb group (n = 8). anti-TNFα mAb, anti-tumor necrosis factor-alpha monoclonal antibody. https://doi.org/10.1371/journal.pone.0283822.g001
Source publication
The risk of malignant tumor progression has been a concern associated with the use of anti-tumor necrosis factor-alpha monoclonal antibody (anti-TNFα mAb). On the contrary, recent observational studies have reported negatively on this risk and instead suggested that anti-TNFα mAb acts as a tumor suppressor in inflammatory carcinogenesis models and...
Contexts in source publication
Context 1
... subjected to orthotopic transplantation were intraperitoneally administered 1 mg of anti-TNFα mAb (MP6-XT22; BioLegend) every 7 days, as shown in Fig 1A (anti-TNFα mAb group, n = 8). ...
Context 2
... were subjected to orthotopic transplantation, and 1 mg of anti-TNFα mAb was administered intraperitoneally every 7 days as shown in Fig 1A. In the anti-TNFα mAb group, a macroscopic reduction in tumor size was observed compared with that in the control group, along with a significant reduction in tumor weight and volume (Fig 1B and 1C). ...
Context 3
... were subjected to orthotopic transplantation, and 1 mg of anti-TNFα mAb was administered intraperitoneally every 7 days as shown in Fig 1A. In the anti-TNFα mAb group, a macroscopic reduction in tumor size was observed compared with that in the control group, along with a significant reduction in tumor weight and volume (Fig 1B and 1C). No apparent lymph node or liver metastases were observed in both groups. ...
Similar publications
Background
Influenza A viruses (IAVs) have long posed a threat to humans, occasionally causing significant morbidity and mortality. The initial immune response is triggered by infected epithelial cells, alveolar macrophages and dendritic cells. However, an exaggerated innate immune response can result in severe lung injury and even host mortality....
Citations
Simple Summary
In its early stages, colorectal cancer (CRC) is a localized tumor, but when it metastasizes, it has dramatic consequences. Murine models in CRC research are important tools for advancing the knowledge in diagnostic and treatment of this pathology. The present review aims to provide a variety of murine models in CRC research describing their particular advantages and drawbacks.
Abstract
Colorectal cancer (CRC) is the third most prevalent malignancy worldwide and in both sexes. Numerous animal models for CRC have been established to study its biology, namely carcinogen-induced models (CIMs) and genetically engineered mouse models (GEMMs). CIMs are valuable for assessing colitis-related carcinogenesis and studying chemoprevention. On the other hand, CRC GEMMs have proven to be useful for evaluating the tumor microenvironment and systemic immune responses, which have contributed to the discovery of novel therapeutic approaches. Although metastatic disease can be induced by orthotopic injection of CRC cell lines, the resulting models are not representative of the full genetic diversity of the disease due to the limited number of cell lines suitable for this purpose. On the other hand, patient-derived xenografts (PDX) are the most reliable for preclinical drug development due to their ability to retain pathological and molecular characteristics. In this review, the authors discuss the various murine CRC models with a focus on their clinical relevance, benefits, and drawbacks. From all models discussed, murine CRC models will continue to be an important tool in advancing our understanding and treatment of this disease, but additional research is required to find a model that can correctly reflect the pathophysiology of CRC.
